This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Smokers Are At High Risk for Low Back Pain, ... Smokers are at high risk for low back pain, and also have higher ... (20 Feb 2019)
Temperatures Rising: Patients Taking ... Patients taking diuretics are often at risk for low potassium ... (20 Feb 2019)
Hormone therapy may increase cardiovascular ... Patients receiving hormone therapy as part of their ... (20 Feb 2019)
Avoiding Selfie Elbow, Texting Thumb Specialists are seeing more and more repetitive stress injuries ... (20 Feb 2019)
Adolescent Female Blood Donors At Risk For ... New public health measures could help protect this vulnerable ... (20 Feb 2019)
Friday, 03 August 2018 13:13

Ketamine Has Potential Therapeutic Role in Adolescents with Treatment-Resistant Depression Featured

Rate this item
(0 votes)

A new study has shown a significant average decrease in the Children’s Depression Rating Scale (42.5%) among adolescents with treatment-resistant depression (TRD) who were treated with intravenous ketamine.

The study, which demonstrated the tolerability and potential role of ketamine as a treatment option for adolescents with TRD, is published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Child and Adolescent Psychopharmacology website.

The article entitled “Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study” was coauthored by Kathryn Cullen, MD, University of Minnesota Medical School, Minneapolis, and a team of researchers from University of Minnesota, Hennepin County Medical Center (Minneapolis, MN), and Mayo Clinic (Rochester, MN).

The study participants were young adults aged 12-18 years who had failed two previous trials of antidepressants. They received six ketamine infusions over 2 weeks. The treatment was well tolerated. Based on the Children’s Depression Rating Scale scores, 38% of participants met the criteria for clinical response and remission.

“The field is excited about a potential new agent for adolescents with treatment resistant depression. We look forward to additional studies of ketamine to validate this treatment,” saysHarold S. Koplewicz, MD, Editor in Chief of theJournal of Child and Adolescent Psychopharmacologyand President of the Child Mind Institute in New York.


Source: Mary Ann Liebert, Inc., Publishers
Full bibliographic information
Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study
Journal of Child and Adolescent Psychopharmacology. 

Read 448 times Last modified on Saturday, 04 August 2018 07:13

Latest news

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…